Compare Becton Dickinson and Co (BDX) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Symbotic Inc — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Symbotic Inc trades at $43.74 (market cap $5.55B). The key difference: Becton Dickinson and Co is far larger — about 7.5× Symbotic Inc's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals.
| BDX | SYM | |
|---|---|---|
Market Cap | $41.51B | $5.55B |
Sector | Health | Technology |
52-Week High | $185.39 | $87.30 |
52-Week Low | $135.49 | $38.57 |
Enterprise Value | $57.97B | $3.54B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Symbotic Inc. (SYM) trades at $42.43, down 2.77% on the day, with technical indicators signaling a bearish trend. The company reported revenue of $2.25 billion in 2025 but posted a net loss of $16.94 million, though gross margins improved to 20.43%. Recent news highlights the acquisition of ARMS Innovations, expanding its AI-powered warehouse optimization solutions. Analyst consensus remains positive with a $57.50 price target, but mixed earnings performance and high valuation ratios present challenges.
Outlook: SYM shows potential in the growing robotics and automation sector, supported by strong operating cash flow and strategic acquisitions. However, profitability concerns, high EV/EBITDA of 240.06, and competitive pressures pose significant risks. Investors should weigh the bullish analyst sentiment against fundamental weaknesses and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
